Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Total Non-Current Liabilities (2019 - 2021)

Nurix Therapeutics (NRIX) has disclosed Total Non-Current Liabilities for 3 consecutive years, with $117.1 million as the latest value for Q3 2021.

  • On a quarterly basis, Total Non-Current Liabilities rose 13.23% to $117.1 million in Q3 2021 year-over-year; TTM through Aug 2021 was $117.1 million, a 13.23% increase, with the full-year FY2020 number at $105.2 million, up 103.02% from a year prior.
  • Total Non-Current Liabilities was $117.1 million for Q3 2021 at Nurix Therapeutics, down from $119.0 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $125.7 million in Q1 2021 to a low of $51.8 million in Q4 2019.
  • A 3-year average of $103.7 million and a median of $111.1 million in 2020 define the central range for Total Non-Current Liabilities.
  • Peak YoY movement for Total Non-Current Liabilities: skyrocketed 103.02% in 2020, then increased 13.23% in 2021.
  • Nurix Therapeutics' Total Non-Current Liabilities stood at $51.8 million in 2019, then surged by 103.02% to $105.2 million in 2020, then increased by 11.25% to $117.1 million in 2021.
  • Per Business Quant, the three most recent readings for NRIX's Total Non-Current Liabilities are $117.1 million (Q3 2021), $119.0 million (Q2 2021), and $125.7 million (Q1 2021).